

## Lilly Cares Foundation 2018 State-Level Results

### Diabetes Medications

Basaglar® (insulin glargine injection); Humalog® (insulin lispro injection); Humulin® (human insulin [rDNA origin]); Glucagon (glucagon for injection [rDNA origin]); Trulicity® (dulaglutide)

	Value of Medications based on Average Wholesale Price	Patients Served
AK	\$ 220,000	37
AL	\$ 11,100,000	1,830
AR	\$ 1,600,000	258
AZ	\$ 2,200,000	330
CA	\$ 6,100,000	1,125
CO	\$ 1,200,000	193
CT	\$ 680,000	131
DC	\$ 33,000	8
DE	\$ 820,000	121
FL	\$ 24,000,000	4,211
GA	\$ 20,400,000	3,341
HI	\$ 16,000	4
IA	\$ 1,900,000	274
ID	\$ 3,900,000	599
IL	\$ 6,100,000	954
IN	\$ 11,700,000	1,875
KS	\$ 8,100,000	1,281
KY	\$ 3,600,000	549
LA	\$ 3,000,000	543
MA	\$ 1,100,000	156
MD	\$ 2,300,000	376
ME	\$ 3,200,000	514
MI	\$ 5,600,000	899
MN	\$ 2,200,000	395
MO	\$ 12,500,000	2,051
MS	\$ 4,700,000	765
MT	\$ 620,000	107
NC	\$ 27,800,000	4,391
ND	\$ 330,000	67
NE	\$ 5,900,000	886
NH	\$ 1,000,000	160
NJ	\$ 3,000,000	493
NM	\$ 310,000	59
NV	\$ 690,000	113
NY	\$ 3,800,000	598
OH	\$ 14,400,000	2,360
OK	\$ 6,400,000	1,027
OR	\$ 3,100,000	533
PA	\$ 9,100,000	1,548
PR	\$ 35,000	9
RI	\$ 980,000	138
SC	\$ 5,900,000	950
SD	\$ 1,200,000	190
TN	\$ 13,500,000	1,965
TX	\$ 42,200,000	6,978
UT	\$ 5,300,000	829
VA	\$ 25,600,000	4,685
VT	\$ 50,000	13
WA	\$ 2,300,000	373
WI	\$ 5,300,000	788
WV	\$ 2,100,000	313
WY	\$ 970,000	165

Basaglar®, Humalog®, Humulin®, and Trulicity® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Mental Health Medications		
Cymbalta® (duloxetine delayed-release capsules); Prozac® (fluoxetine); Strattera® (atomoxetine); Symbyax® (olanzapine and fluoxetine); Zyprexa® (olanzapine)		
	Value of Medications based on Average Wholesale Price	Patients Served
AK	\$ 44,000	13
AL	\$ 6,500,000	1,509
AR	\$ 240,000	68
AZ	\$ 120,000	33
CA	\$ 480,000	121
CO	\$ 250,000	51
CT	\$ 24,000	7
DC	\$ 3,000	2
DE	\$ 38,000	13
FL	\$ 13,500,000	3,165
GA	\$ 19,600,000	4,084
IA	\$ 150,000	41
ID	\$ 5,400,000	945
IL	\$ 540,000	137
IN	\$ 1,600,000	403
KS	\$ 5,400,000	1,080
KY	\$ 270,000	89
LA	\$ 580,000	155
MA	\$ 24,000	9
MD	\$ 280,000	68
ME	\$ 2,200,000	426
MI	\$ 520,000	133
MN	\$ 170,000	37
MO	\$ 5,500,000	1,154
MS	\$ 2,700,000	658
MT	\$ 300,000	67
NC	\$ 20,400,000	4,036
ND	\$ 140,000	31
NE	\$ 4,600,000	929
NH	\$ 160,000	36
NJ	\$ 340,000	63
NM	\$ 56,000	12
NV	\$ 49,000	16
NY	\$ 490,000	88
OH	\$ 1,200,000	293
OK	\$ 20,500,000	4,243
OR	\$ 330,000	80
PA	\$ 1,000,000	275
RI	\$ 38,000	7
SC	\$ 3,800,000	744
SD	\$ 3,100,000	626
TN	\$ 7,900,000	1,594
TX	\$ 73,600,000	14,665
UT	\$ 1,100,000	263
VA	\$ 21,100,000	4,294
VT	\$ 7,000	1
WA	\$ 150,000	36
WI	\$ 790,000	147
WV	\$ 340,000	96
WY	\$ 1,300,000	263

Cymbalta®, Prozac®, Strattera®, Symbyax®, and Zyprexa® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

### Cancer Medications

Alimta® (pemetrexed for injection); Cyramza® (ramucirumab); Erbitux® (cetuximab); Gemzar® (gemcitabine); Lartruvo® (olaratumab); Portrazza® (necitumumab); Verzenio® (abemaciclib)

	Value of Medications based on Average Wholesale Price	Patients Served
AK	\$ 61,000	2
AL	\$ 1,700,000	50
AR	\$ 550,000	18
AZ	\$ 1,500,000	37
CA	\$ 3,200,000	69
CO	\$ 800,000	22
CT	\$ 360,000	14
DE	\$ 340,000	5
FL	\$ 9,000,000	244
GA	\$ 3,300,000	86
HI	\$ 150,000	5
IA	\$ 720,000	15
ID	\$ 1,000,000	19
IL	\$ 2,700,000	58
IN	\$ 1,200,000	35
KS	\$ 810,000	27
KY	\$ 1,700,000	31
LA	\$ 760,000	16
MA	\$ 950,000	21
MD	\$ 820,000	19
ME	\$ 280,000	5
MI	\$ 1,600,000	43
MN	\$ 1,100,000	20
MO	\$ 1,900,000	50
MS	\$ 1,500,000	38
MT	\$ 41,000	1
NC	\$ 3,200,000	83
ND	\$ 95,000	1
NE	\$ 650,000	21
NH	\$ 170,000	5
NJ	\$ 2,800,000	62
NM	\$ 160,000	5
NV	\$ 580,000	18
NY	\$ 2,300,000	54
OH	\$ 3,300,000	84
OK	\$ 1,600,000	46
OR	\$ 1,100,000	24
PA	\$ 2,300,000	55
PR	\$ 82,000	3
SC	\$ 2,000,000	62
SD	\$ 190,000	4
TN	\$ 3,600,000	104
TX	\$ 11,900,000	321
UT	\$ 260,000	7
VA	\$ 2,600,000	79
VT	\$ 180,000	2
WA	\$ 750,000	18
WI	\$ 1,400,000	29
WV	\$ 450,000	11
WY	\$ 150,000	8

Alimta®, Cyramza®, Erbitux®, Gemzar®, Lartruvo®, Portrazza®, and Verzenio® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

### Other Medications

Cialis® (tadalafil); Effient® (prasugrel); Emgality® (galcanezumab-gnlm) injection; Evista® (raloxifene hydrochloride); Forteo® (teriparatide [rDNA origin] injection); Humatrope® (somatropin) for injection; Olumiant® (baricitinib) tablets; Taltz® (ixekizumab) injection

	Value of Medications based on Average Wholesale Price	Patients Served
AK	\$ 880,000	27
AL	\$ 9,500,000	452
AR	\$ 9,300,000	250
AZ	\$ 10,400,000	310
CA	\$ 27,000,000	934
CO	\$ 9,300,000	266
CT	\$ 2,500,000	75
DC	\$ 95,000	6
DE	\$ 1,100,000	34
FL	\$ 55,400,000	3,168
GA	\$ 18,400,000	878
HI	\$ 790,000	23
IA	\$ 6,800,000	205
ID	\$ 3,600,000	133
IL	\$ 17,100,000	566
IN	\$ 15,300,000	508
KS	\$ 7,200,000	274
KY	\$ 8,300,000	280
LA	\$ 8,700,000	296
MA	\$ 5,700,000	152
MD	\$ 4,800,000	160
ME	\$ 1,200,000	86
MI	\$ 17,300,000	534
MN	\$ 7,400,000	198
MO	\$ 15,200,000	602
MS	\$ 7,500,000	416
MT	\$ 1,400,000	56
NC	\$ 20,700,000	939
ND	\$ 2,700,000	80
NE	\$ 2,200,000	129
NH	\$ 1,500,000	49
NJ	\$ 8,500,000	282
NM	\$ 1,800,000	53
NV	\$ 2,800,000	86
NY	\$ 13,900,000	435
OH	\$ 19,100,000	574
OK	\$ 14,800,000	533
OR	\$ 5,500,000	154
PA	\$ 19,100,000	566
PR	\$ 120,000	10
RI	\$ 520,000	18
SC	\$ 8,900,000	385
SD	\$ 1,700,000	71
TN	\$ 15,600,000	665
TX	\$ 46,600,000	1,860
UT	\$ 4,500,000	166
VA	\$ 13,000,000	806
VT	\$ 650,000	17
WA	\$ 6,300,000	168
WI	\$ 7,200,000	233
WV	\$ 1,800,000	82
WY	\$ 360,000	18

Cialis®, Effient®, Emgality®, Evista®, Forteo®, Humatrope®, Olumiant®, and Taltz® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares Foundation, Inc., Lilly Corporate Center, Indianapolis, IN 46285; Steve Stapleton, President, [stapleton\\_steven\\_j@lilly.com](mailto:stapleton_steven_j@lilly.com)